Equities

Karyopharm Therapeutics Inc

Karyopharm Therapeutics Inc

Actions
  • Price (USD)1.06
  • Today's Change-0.035 / -3.21%
  • Shares traded714.84k
  • 1 Year change-57.80%
  • Beta0.2727
Data delayed at least 15 minutes, as of May 24 2024 19:41 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. It is developing and commercializing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead asset, XPOVIO (selinexor), is marketed in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. The Company is engaged in evaluating selinexor in certain hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, mycosis fungoides (MF) and diffuse large B-cell lymphoma (DLBCL). The Company’s product candidate, eltanexor, oral SINE compound that, like selinexor, selectively blocks the nuclear export protein XPO1.

  • Revenue in USD (TTM)140.46m
  • Net income in USD-146.34m
  • Incorporated2008
  • Employees325.00
  • Location
    Karyopharm Therapeutics Inc85 Wells AveNEWTON CENTER 02459-3298United StatesUSA
  • Phone+1 (617) 658-0600
  • Fax+1 (302) 655-5049
  • Websitehttps://karyopharm.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Nuvectis Pharma Inc0.00-22.38m122.62m13.00--8.74-----1.40-1.400.000.76390.00----0.00-124.61---170.23--------------0.00-------16.64------
Rezolute Inc0.00-58.21m122.81m51.00--1.73-----1.14-1.140.001.770.00----0.00-52.46-58.48-55.28-63.38------------0.00-------26.13--92.29--
Citius Pharmaceuticals Inc0.00-37.35m123.62m22.00--1.37-----0.2367-0.23670.000.49890.00----0.00-37.14-30.26-39.48-32.11------------0.00-------0.1589------
Genelux Corp8.00k-25.78m124.19m23.00--8.10--15,523.13-0.9811-0.98110.00030.56790.0004----347.83-131.24---246.21-------322,287.50------0.00---98.46---443.44------
aTyr Pharma Inc588.00k-53.93m124.22m56.00--1.46--211.26-0.9029-0.90290.00991.240.0047--0.286810,500.00-43.13-45.45-48.85-52.74-----9,172.11-784.19----0.021---96.60---11.14--47.98--
Regulus Therapeutics Inc0.00-31.37m125.69m28.00--1.17-----1.46-1.460.001.640.00----0.00-41.50-53.74-45.91-76.96-------715.58----0.005-------6.05--94.54--
Adicet Bio Inc0.00-139.79m125.73m143.00--0.4858-----2.95-2.950.003.150.00----0.00-46.75-37.03-49.70-40.28-------748.46----0.00---100.00---104.41--65.27--
Scpharmaceuticals Inc17.63m-57.71m126.91m135.00--5.17--7.20-1.49-1.490.45450.68140.17130.75664.02130,607.40-56.07-38.23-62.13-42.3171.69---327.29-1,360.165.44-16.600.6159-------48.79------
FibroGen Inc167.49m-240.46m127.33m486.00------0.7602-2.45-2.451.70-2.290.37041.185.05344,635.80-53.71-30.62-124.24-42.3175.4693.52-145.02-119.081.27-36.51----4.99-7.053.21---20.67--
Sangamo Therapeutics Inc18.76m-328.05m128.22m405.00--2.22--6.84-1.86-1.860.10570.27840.0659--4.8646,311.11-115.20-26.09-139.17-31.04-----1,749.06-136.53----0.00--58.3415.85-34.09---13.25--
Karyopharm Therapeutics Inc140.46m-146.34m128.30m325.00------0.9135-1.28-1.281.22-1.450.52981.674.24432,187.70-55.19-53.02-72.56-65.8596.0897.18-104.18-125.152.99-9.662.25---7.0336.9313.43------
Corvus Pharmaceuticals Inc0.00-24.86m129.48m28.00--3.04-----0.5113-0.51130.000.68040.00----0.00-50.58-38.31-59.70-43.34-----------12.880.00------34.57---37.45--
Repare Therapeutics Inc97.86m-45.69m131.58m179.00--0.5624--1.34-1.10-1.102.305.510.3265--9.22546,698.30-15.25-23.40-18.73-26.37-----46.69-162.76----0.00---61.21---222.91--27.16--
Beyondspring Inc1.75m-21.03m133.87m35.00------76.45-0.5392-0.53920.0449-0.68680.0493----48,638.89-61.80-75.50-88.85-96.48-----1,253.46-4,977.12--------29.61--36.82---13.54--
Data as of May 24 2024. Currency figures normalised to Karyopharm Therapeutics Inc's reporting currency: US Dollar USD

Institutional shareholders

41.54%Per cent of shares held by top holders
HolderShares% Held
Avidity Partners Management LPas of 31 Mar 20248.30m7.13%
The Vanguard Group, Inc.as of 31 Mar 20248.11m6.97%
BlackRock Fund Advisorsas of 31 Mar 20247.84m6.74%
Palo Alto Investors LPas of 31 Mar 20245.10m4.38%
Eversept Partners LPas of 31 Mar 20245.02m4.31%
Adage Capital Management LPas of 31 Mar 20243.50m3.01%
Citadel Advisors LLCas of 31 Mar 20243.10m2.66%
Marshall Wace LLPas of 31 Mar 20242.60m2.23%
Geode Capital Management LLCas of 31 Mar 20242.52m2.16%
SSgA Funds Management, Inc.as of 31 Mar 20242.29m1.96%
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.